Source: International Congress 2018 – Asthma management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Ly (Mountain View, United States of America), Y. Zheng (Mountain View, United States of America), J. Griffiths (Gaithersburg, United States of America), R. Van Der Merwe (Cambridge, United Kingdom), B. Agoram (Mountain View, United States of America), L. Roskos (Gaithersburg, United States of America). Exposure-response analysis of tezepelumab in patients with severe asthma to guide phase 3 dose selection. 1688

Member's Comments

No comment yet.

Related content which might interest you: Population pharmacokinetic and exposure-response analyses to support fixed dosing of tezepelumab in patients with severe asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Effect of high or low-medium accumulated dose regimes of systemic corticosteroids for hospitalised patients with exacerbated chronic obstructive pulmonary disease: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data Year: 2021 Factors affecting patients’ decision to adjust treatment; secondary analysis of a randomised trial of treatment optimisation in patients with severe asthma Source: Virtual Congress 2021 – Asthma burden and management I Year: 2021 Decaf score for predicting treatment escalation in exacerbations of COPD Source: Virtual Congress 2020 – Clinical and functional evaluation of COPD Year: 2020 Reslizumab for uncontrolled eosinophilic asthma in patients who experienced a single exacerbation in the previous year: sub-analysis of two phase 3 trials Source: International Congress 2017 – Asthma management Year: 2017 COPD exacerbations in the phase 3 revefenacin clinical trial program Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018 A realistic study assessing inhaled treatment compliance in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 25s Year: 2001 Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPD Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Latent class analyses used to study phenotypes in severe COPD with exacerbation. A pilot study Source: Annual Congress 2010 - Epidemiological data for smoking control Year: 2010 Pooled analyses of five phase 2b studies support dose selection of glycopyrrolate-formoterol (GFF) MDI (PT003) 18/9.6 μg for phase III development Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Effect of high extrafine strength (HS) ICS-containing triple therapy on exacerbations in patients with severe asthma and persistent airflow limitation: Post-hoc analysis of the TRIGGER study Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 Persistence of clinical criteria of chronic bronchitis in patients with COPD over time: A longitudinal analysis of the TRACE cohort. Source: International Congress 2017 – Markers of COPD progression Year: 2017 Small airways function: evaluation in a population of adult patients with severe asthma and potential use as a response biomarker for anti-IL5 therapy Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 COPD in the time of COVID-19: an analysis of acute exacerbations and reported behavioural changes in patients with COPD Source: ERJ Open Res, 7 (1) 00718-2020; 10.1183/23120541.00718-2020 Year: 2021 Adding montelukast versus doubling the budesonide dose in persistent asthma: a subgroup analysis of the COMPACT study Source: Eur Respir J 2002; 20: Suppl. 38, 388s Year: 2002 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Early occurrence of any COPD exacerbation predicts further higher risk of moderate/severe exacerbations regardless of recording tool: the FLAME study Source: International Congress 2017 – Management of COPD Year: 2017 A new treatment algorithm for acute exacerbation of IPF: a retrospective cohort study. Source: International Congress 2019 – Recent developments in intensive care unit medicine Year: 2019 Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis Source: Eur Respir J, 56 (4) 2000151; 10.1183/13993003.00151-2020 Year: 2020